A groundbreaking analysis presented at the American College of Cardiology’s Annual Scientific Session has revealed a compelling link between receiving the shingles vaccine and a substantial reduction in major heart-related events among individuals already diagnosed with atherosclerotic cardiovascular disease. The research indicates that those who underwent vaccination experienced a nearly 50% lower incidence of serious cardiac episodes within a year of immunization compared to their unvaccinated counterparts. This finding expands upon a growing body of evidence suggesting that the vaccine, primarily developed to combat the varicella-zoster virus, may confer benefits extending far beyond its intended purpose, potentially offering protection against cardiovascular ailments and even cognitive decline.
The extensive investigation meticulously examined the health records of over 246,822 adults across the United States who had been diagnosed with atherosclerotic heart disease, a condition characterized by the gradual accumulation of plaque within the arterial walls. Dr. Robert Nguyen, a resident physician at the University of California, Riverside, and the principal investigator of the study, emphasized the vaccine’s consistently demonstrated cardioprotective qualities, which have been repeatedly observed to mitigate risks of heart attack, stroke, and mortality. He posited that these protective effects could be even more pronounced within the highest-risk demographic – individuals already managing pre-existing cardiovascular conditions – than in the general population.
The biological mechanisms underpinning the shingles vaccine’s potential impact on cardiovascular health are multifaceted and rooted in the intricate relationship between viral reactivation and systemic inflammation. The Centers for Disease Control and Prevention (CDC) currently recommends the shingles vaccine for adults aged 50 and older, as well as for younger individuals with compromised immune systems. The vaccine targets herpes zoster, commonly known as shingles, a debilitating condition characterized by a painful blistering rash that can sometimes lead to prolonged post-herpetic neuralgia. Shingles arises when the varicella-zoster virus, the same virus responsible for chickenpox, reawakens within the body, often dormant for decades following the initial infection.
Prior scientific inquiries have illuminated a direct correlation between shingles outbreaks and an increased propensity for blood clot formation, particularly in proximity to the brain and heart. This heightened risk of thrombosis has been identified as a significant contributing factor to the incidence of heart attacks, strokes, and venous thromboembolism. Consequently, by effectively preventing the occurrence of shingles, the vaccine may indirectly diminish the likelihood of these life-threatening thrombotic events, thereby offering a protective buffer for the cardiovascular system.
The study’s robust findings were derived from an analysis of data sourced from TriNetX, a comprehensive digital health platform aggregating anonymized medical records from millions of Americans. The research team meticulously identified and analyzed a cohort of adults aged 50 years and above who had been diagnosed with atherosclerotic disease between the years 2018 and 2025. The meticulously constructed comparison group comprised 123,411 individuals who had received at least one dose of either the Shingrix or Zostavax vaccine, matched precisely with an equal number of unvaccinated individuals. Crucially, both cohorts were carefully scrutinized to ensure comparability in terms of demographic characteristics and the presence of other co-existing health conditions, thereby minimizing potential confounding variables.
Researchers meticulously tracked cardiovascular outcomes within a defined period, commencing one month after vaccination (or a corresponding timeframe for the unvaccinated group) and extending for a full year. Across all assessed metrics, the vaccinated cohort demonstrated a statistically significant reduction in adverse events. Specifically, these individuals exhibited a 46% lower likelihood of experiencing a major adverse cardiac event. Furthermore, their risk of mortality from any cause was reduced by an impressive 66%. The study also reported substantial decreases in the incidence of specific cardiovascular conditions: heart attack risk was lowered by 32%, stroke risk by 25%, and heart failure incidence by 25%.
Dr. Nguyen underscored the clinical significance of these risk reductions, drawing a parallel between the magnitude of these benefits and those observed from cessation of smoking, a well-established intervention for cardiovascular health improvement. He reiterated that these findings lend substantial weight to the existing recommendations for adults over the age of 50 to undergo shingles vaccination. He articulated a strong belief that vaccines represent one of the most potent medical tools available for disease prevention. He acknowledged the challenges posed by misinformation, particularly in the current digital age, and expressed hope that these compelling results would provide a further compelling reason for individuals to opt for vaccination.
While the study offers compelling insights, it is essential to acknowledge certain limitations inherent in its design. The primary analysis focused on outcomes observed within the initial year post-vaccination, meaning the long-term ramifications of the vaccine on cardiovascular health remain an area for continued investigation. However, a preceding study, published in 2025, had already indicated that shingles vaccination was associated with a 23% reduction in cardiovascular events among generally healthy adults, with potential benefits extending up to eight years.
Another consideration is the potential for self-selection bias, wherein individuals who opt for vaccination might also be more inclined to adopt healthier lifestyle behaviors across the board. Although the researchers diligently controlled for a range of health-related and socioeconomic factors – encompassing aspects such as housing and economic circumstances, social environment, employment status, and educational attainment – the possibility of residual influence from these unmeasured behavioral differences cannot be entirely discounted. Nevertheless, the sheer scale of the study’s participant pool, coupled with its sophisticated statistical methodologies, collectively furnishes robust evidence supporting a meaningful association between shingles vaccination and a reduced risk of cardiovascular events.
Dr. Nguyen is scheduled to formally present the comprehensive findings of this research, titled "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease," on Monday, March 30th, at 12:30 p.m. Central Time / 17:30 Coordinated Universal Time, within Posters, Hall E, at the American College of Cardiology’s Annual Scientific Session.
About the Author
